Bio-Techne TECH Diagnostics And Spatial Biology — Selling General And Administrative Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's diagnostics and spatial biology — selling general and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's diagnostics and spatial biology — selling general and administrative expense?
- Bio-Techne (TECH) reported diagnostics and spatial biology — selling general and administrative expense of $27.62M in Q1 2026.
- How has Bio-Techne's diagnostics and spatial biology — selling general and administrative expense changed year-over-year?
- Bio-Techne's diagnostics and spatial biology — selling general and administrative expense decreased by 17.4% year-over-year, from $33.42M to $27.62M.
- What is the long-term trend for Bio-Techne's diagnostics and spatial biology — selling general and administrative expense?
- Over 2 years (2023 to 2025), Bio-Techne's diagnostics and spatial biology — selling general and administrative expense has grown at a 15.6% compound annual growth rate (CAGR), from $101.81M to $136.1M.
- What does diagnostics and spatial biology — selling general and administrative expense mean?
- The overhead and operating costs required to run the sales and administrative functions of this segment.
- How do you interpret diagnostics and spatial biology — selling general and administrative expense?
- High expenses relative to revenue may indicate heavy investment in growth, while declining ratios suggest operating leverage.
- How does diagnostics and spatial biology — selling general and administrative expense compare across companies?
- Common operating expense category for all public companies.